Hinova Pharmaceuticals Inc
SSE:688302
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
28.6
67.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
H
|
Hinova Pharmaceuticals Inc
SSE:688302
|
4.7B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
969.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.3B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
93.8B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Hinova Pharmaceuticals Inc
Glance View
Hinova Pharmaceuticals, Inc. engages in the research and development of pharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 160 full-time employees. The company went IPO on 2022-04-12. The firm focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The firm's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The firm has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The firm conducts clinical tests in domestic and overseas areas.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Hinova Pharmaceuticals Inc is -1 337.2%, which is above its 3-year median of -77 885.3%.
Over the last 3 years, Hinova Pharmaceuticals Inc’s Operating Margin has increased from -20 467% to -1 337.2%. During this period, it reached a low of -235 121.3% on Jun 30, 2024 and a high of -1 337.2% on Jul 30, 2025.